pubmed-article:21126942 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:21126942 | lifeskim:mentions | umls-concept:C0024141 | lld:lifeskim |
pubmed-article:21126942 | lifeskim:mentions | umls-concept:C0383327 | lld:lifeskim |
pubmed-article:21126942 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
pubmed-article:21126942 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
pubmed-article:21126942 | lifeskim:mentions | umls-concept:C0243173 | lld:lifeskim |
pubmed-article:21126942 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:21126942 | pubmed:dateCreated | 2010-12-17 | lld:pubmed |
pubmed-article:21126942 | pubmed:abstractText | Overproduction of inflammation-related cytokines plays an important role in systemic lupus erythematosus (SLE). A crucial cytokine is IL-18, a member of the IL-1 family involved in the regulation of both innate and acquired immune responses. The aim of this study was to evaluate free IL-18 levels in the serum and urine of SLE patients, in order to establish their relationship with other biomarkers of disease activity. Serum and urine levels of IL-18 and IL-18BP were measured by ELISA in 50 SLE patients and in 32 healthy subjects; free IL-18 was calculated using the law of mass action. Serum levels of total IL-18, IL-18BP and free IL-18 were higher in SLE patients than in healthy controls. Total and free serum IL-18 levels were higher in patients with active disease (with nephritis or active non-renal disease), and correlated with the ECLAM score. Urinary levels of total and free IL-18 were higher in patients than in controls, but did not correlate with disease activity. The data collected in this study show that increased levels of both IL-18 and its natural inhibitor IL-18BP, characterise SLE. Despite the overproduction of IL-18BP, free IL-18 is still significantly higher in SLE patients than in controls, and its serum levels are a marker of disease activity. | lld:pubmed |
pubmed-article:21126942 | pubmed:language | eng | lld:pubmed |
pubmed-article:21126942 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21126942 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:21126942 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21126942 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21126942 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21126942 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21126942 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:21126942 | pubmed:month | Dec | lld:pubmed |
pubmed-article:21126942 | pubmed:issn | 1148-5493 | lld:pubmed |
pubmed-article:21126942 | pubmed:author | pubmed-author:DinarelloChar... | lld:pubmed |
pubmed-article:21126942 | pubmed:author | pubmed-author:PratesiFederi... | lld:pubmed |
pubmed-article:21126942 | pubmed:author | pubmed-author:MiglioriniPao... | lld:pubmed |
pubmed-article:21126942 | pubmed:author | pubmed-author:BoraschiDiana... | lld:pubmed |
pubmed-article:21126942 | pubmed:author | pubmed-author:QuattroniPaol... | lld:pubmed |
pubmed-article:21126942 | pubmed:author | pubmed-author:AnzilottiCons... | lld:pubmed |
pubmed-article:21126942 | pubmed:author | pubmed-author:BargagnaMarco... | lld:pubmed |
pubmed-article:21126942 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:21126942 | pubmed:day | 1 | lld:pubmed |
pubmed-article:21126942 | pubmed:volume | 21 | lld:pubmed |
pubmed-article:21126942 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:21126942 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:21126942 | pubmed:pagination | 264-71 | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:meshHeading | pubmed-meshheading:21126942... | lld:pubmed |
pubmed-article:21126942 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:21126942 | pubmed:articleTitle | Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. | lld:pubmed |
pubmed-article:21126942 | pubmed:affiliation | Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, Via Roma 67, Pisa, Italy. p.migliorini@med.unipi.it | lld:pubmed |
pubmed-article:21126942 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:21126942 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
entrez-gene:3606 | entrezgene:pubmed | pubmed-article:21126942 | lld:entrezgene |
entrez-gene:10068 | entrezgene:pubmed | pubmed-article:21126942 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21126942 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21126942 | lld:entrezgene |